Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Labs Will Help Artus Market, Distribute PCR-based SARS Test

NEW YORK, May 15 - Abbott Laboratories has penned a worldwide marketing and distribution agreement with German-based Artus for what is believed to be the first commercial PCR-based test to detect a form of the coronavirus linked to SARS.


Terms of the agreement call for Artus to manufacture the test, and for Abbott to  market and distribute it initially for use on the Roche LightCycler thermal cycler system in North America, the UK, Germany, and Austria. In addition, within several weeks the test will be available worldwide on the Applied Biosystems ABI Prism 7000 Sequence Detection System.

 

Abbott will also help Artus submit the test to the US Food and Drug Administration "as quickly as possible," and will market and distribute it through its molecular diagnostics alliance with Celera Diagnostics. That alliance, struck in June 2002, was designed to develop and market "a broad menu" of molecular diagnostics for various "unmet" undisclosed diagnostic needs.

The test, developed by Artus with the Bernhard-Nocht-Institute for Tropical Medicine  in Hamburg, Germany, has already been introduced by Artus in April to countries in Europe and Asia. The Abbott agreement will "supplement" this distribution network, Artus said. The test has also been provided to laboratories overseen by the World Health Organization and "other major clinical sites" conducting research on the virus.

 

"We believe this new test is sensitive enough to detect the virus in the early stages of infection," said James Koziarz, vice president, diagnostic products research and development, Abbott Labs.

 



GenomeWeb Coverage of SARS

 

German Group Explores SARS Coronavirus Proteinase Structure (May 13, 2003)

///issues/news//121942-1.html"ONT-SIZE: 12pt; FILTER: ; MARGIN: 0in 0in 0pt; BOTTOM: 0px; FONT-FAMILY: 'Times New Roman'">Study Analyzes How SARS Virus Changed As It Spread Across the Globe (May 9, 2003)

///issues/news//121942-1.html"/font>

CombiMatrix Develops siRNA to Target SARS Virus (May 7, 2003)

Affymetrix to Offer SARS GeneChip (May 6, 2003)

///issues/news//121942-1.html" (May 2, 2003)

Roche to Launch RT-PCR-based SARS Diagnostic by July (April 28, 2003)

///issues/news//121942-1.html"

CombiMatrix's Ali Arjomand on Developing a SARS Microarray ( ///issues/news//121942-1.html"tyle="FONT-SIZE: 10pt; COLOR: #040000">University of Manitoba Proteomics Researchers Tackle SARS Virus Proteins ( ///issues/news//121942-1.html">   (April 21, 2003)

Singapore Team Finishes SARS Virus Genome; Canadian Scientists Identify Viral Proteins  (April 17, 2003)

///issues/news//121942-1.html"">CombiMatrix Creates Microarray Based on SARS Genome Data   (April 16, 2003)
///issues/news//121942-1.html"/font>

CDC Completes SARS Virus Genome Draft On Heels of Canadian Team  (April 14, 2003)

///issues/news//121942-1.html"

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.